Senate approves $212.5M increase to improve NCI success rates; FY20 spending bills provide new funding for childhood cancer, raise tobacco-purchase age to 21 – The Cancer Letter

publication date: Dec. 20, 2019By Alexandria Carolan & Matthew Bin Han OngThe Senate passed $1.4 trillion in spending bills Dec. 19 that includes a $212.5 million increase for NCI to cope with an avalanche of grant applications and improve the institute’s declining success rates.The bills also fund NCI’s Childhood Cancer Data Initiative, and include a mandate that raises the tobacco-purchase age…

Read the full article here

Source: cancerletter.com

Categories: Hem/Oncs

Tweets with this article

Wafik S. El-Deiry, MD, PhD, FACP

Senate approves $212.5M increase to improve NCI success rates; FY20 spending bills provide new funding for childhood cancer, raise tobacco-purchase age to 21 https://t.co/tKs9YVPzlT

UT Southwestern breaks ground on $177M radiation oncology campus in Fort Worth – The Cancer Letter

UT Southwestern Medical Center broke ground May 12 on a $177 million radiation oncology campus that will provide advanced therapies for patients of Fort Worth,…

The Cancer Letter May 19, 2025

Executive order sets drug price targets for most-favored-nations – The Cancer Letter

On May 12, President Trump signed an executive order directing the administration to communicate most-favored-nation drug price targets to pharmaceutical manufacturers for sales in the…

The Cancer Letter May 19, 2025

What Is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

Find information about how PLUVICTO works as a target therapy that delivers radiation treatment to PSMA+ cells. See full prescribing and safety info.

Wafik S. El-Deiry, MD, PhD, FACP May 18, 2025

Neuroendocrine prostate cancer drivers SOX2 and BRN2 confer differential responses to imipridones ONC201, ONC206, and ONC212 in prostate cancer cell lines – PubMed

The results suggest that treatment of castrate-resistant prostate cancer by imipridones may not be substantially affected by neuroendocrine differentiation as a therapy-resistance mechanism. The results…

Wafik S. El-Deiry, MD, PhD, FACP May 18, 2025

Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer

Androgen receptor (AR) signaling is a target in prostate cancer therapy and can be treated with non-steroidal anti-androgens (NSAA) including enzalutamide, and apalutamide for patients…

Wafik S. El-Deiry, MD, PhD, FACP May 18, 2025

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Background ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties…

Wafik S. El-Deiry, MD, PhD, FACP May 18, 2025

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges – The Cancer Letter

In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has…

The Cancer Letter May 18, 2025

Related Articles